Strides Pharma Science has allotted 2,04,500 equity shares under ESOP. Consequent to above, the paid-up share capital of the Company has increased from Rs. 91,95,82,140 consisting of 9,19,58,214 equity shares of Rs. 10/- each to 92,16,27,140 consisting of 9,21,62,714 equity shares of Rs. 10/- each. Powered by Capital Market - Live News

Strides Pharma Science announced that its associate company, OneSource Specialty Pharma has successfully completed the fundraise activity and has allotted equity shares to the marquee domestic and international investors who participated in this issue. OneSource Specialty Pharma has allotted 6,277,909 fully paid up equity shares at a price of Rs 1,276/- (including a premium of Rs 1,275/-) per share on a private placement basis to marquee domestic and international investors. The total consideration received from the allotment stands at Rs 801 crore, valuing OneSource at a pre-money equity valuation of USD 1.65 billion. This milestone reinforces OneSource`s strong positioning as India`s first specialty pharma CDMO and its readiness for robust growth ahead of its proposed listing. Powered by Capital Market - Live News

Strides Pharma Global, Singapore (SPG), a wholly owned step-down subsidiary of Strides Pharma Science, is acquiring balance stake in Strides Pharma International AG (formerly Fairmed Healthcare AG) (Strides Switzerland), a step-down subsidiary of the Company for an aggregate consideration of ~CHF 1.01 million. SPG currently owns 70% stake in Strides Switzerland. As part of business consolidation and to achieve operational synergy, SPG is acquiring the balance 30% stake in Strides Switzerland. Strides Switzerland is strategically positioned to serve key markets in Europe. The acquisition marks a significant milestone in Strides` expansion efforts, further strengthening its position in the region. The business is led by  Oren Weininger, who is the longstanding CEO of Strides Switzerland. Oren shall continue to lead the business in this region. His wealth of experience and expertise will drive company`s continued success and growth in the European market.Powered by Capital Market - Live News

Net profit of Strides Pharma Science reported to Rs 93.23 crore in the quarter ended September 2024 as against net loss of Rs 131.34 crore during the previous quarter ended September 2023. Sales rose 20.18% to Rs 1201.11 crore in the quarter ended September 2024 as against Rs 999.43 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1201.11999.43 20 OPM %18.5711.09 - PBDT169.2668.14 148 PBT118.738.03 1379 NP93.23-131.34 LP Powered by Capital Market - Live News

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live News